Skip to main content

RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

ALISO VIEJO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 24th Annual Needham Virtual Healthcare Conference.

RxSight’s management is scheduled to participate in a fireside chat on Tuesday, April 8, 2025, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. A live and archived webcast of the presentation will be available on the Company’s investor relations website at https://investors.rxsight.com/.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL™/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com

Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  201.18
+2.39 (1.20%)
AAPL  263.88
+8.10 (3.17%)
AMD  203.08
-4.24 (-2.05%)
BAC  52.74
+0.19 (0.36%)
GOOG  302.82
-3.20 (-1.05%)
META  639.26
-0.51 (-0.08%)
MSFT  396.86
-4.46 (-1.11%)
NVDA  184.97
+2.16 (1.18%)
ORCL  153.97
-6.17 (-3.85%)
TSLA  410.63
-6.81 (-1.63%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.